Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-05-28 Director's Dealing
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-05-28 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under the Securities Act, which is a type of offering document related to the issuance of new securities. It details the offering of common stock and warrants, including pricing, underwriting, and risk factors. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2025-05-23 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 22, 2025, by Outlook Therapeutics, Inc. It announces an underwriting agreement for a securities offering involving common stock and warrants. The document details the terms of the offering, the underwriting agreement, and related legal opinions. It does not contain financial statements or detailed financial analysis but rather provides an update on a capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 8080 characters, sufficient to provide substantive details about the financing event. Therefore, the correct classification is CAP with high confidence.
2025-05-23 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of common stock and warrants. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and other offering details. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not an annual or quarterly report, earnings release, management discussion, or any other report type. It is clearly a capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not a report publication announcement or regulatory filing fallback. Confidence is high given the clear identification of the document as a prospectus supplement for a securities offering.
2025-05-22 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.